Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2021 Canadian Surgery Forum: Virtual, online Sept. 21-24, 2021.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Ecological drivers of helminth infection patterns in the Virunga Massif mountain gorilla population.

International journal for parasitology. Parasites and wildlife·2022
Same author

Author Correction: Anthropogenic modification of forests means only 40% of remaining forests have high ecosystem integrity.

Nature communications·2021
Same author

Anthropogenic modification of forests means only 40% of remaining forests have high ecosystem integrity.

Nature communications·2020
Same author

DEMONSTRATION OF THE POTENTIAL AND DIFFICULTIES OF COMBINED TL AND OSL MEASUREMENTS OF TLD-600 AND TLD-700 FOR THE DETERMINATION OF THE DOSE COMPONENTS IN COMPLEX NEUTRON-GAMMA RADIATION FIELDS.

Radiation protection dosimetry·2020
Same author

DOSE DEPENDENCE OF RADIATION INDUCED DAMAGE IN THE THERMOLUMINESCENT RESPONSE OF LIF:Mg,Ti (TLD-100).

Radiation protection dosimetry·2020

Related Experiment Video

Updated: Jul 23, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Consensus perspectives on prophylactic therapy for haemophilia: summary statement.

E Berntorp1, J Astermark, S Björkman

  • 1Department of Coagulation Disorders, Malmö University Hospital, Malmö, Sweden. erik.berntorp@medforsk.mas.lu.se

Haemophilia : the Official Journal of the World Federation of Hemophilia
|April 24, 2003
PubMed
Summary

International experts reached a consensus on updated definitions for prophylactic therapy in severe haemophilia (a bleeding disorder). Recommendations were made for pharmacovigilance and future research directions to optimize patient care.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: Jul 23, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Area of Science:

  • Hematology
  • Pharmacology
  • Clinical Medicine

Background:

  • Severe haemophilia requires prophylactic therapy to prevent bleeding.
  • Current prophylactic strategies necessitate updated definitions and international standards.
  • International consensus is crucial for advancing haemophilia treatment.

Purpose of the Study:

  • To establish a consensus summary from an international conference on prophylactic therapy for severe haemophilia.
  • To revise definitions of primary and secondary prophylaxis.
  • To recommend improvements in pharmacovigilance and identify research priorities.

Main Methods:

  • International conference participation.
  • Consensus development on findings and conclusions.
  • Discussion and agreement on revised definitions and recommendations.

Main Results:

  • Agreement on revised definitions for primary and secondary prophylaxis.
  • Recommendations for an international pharmacovigilance system.
  • Identification of key research questions regarding prophylaxis initiation, cessation, dosing, and long-term effects.

Conclusions:

  • Revised definitions and pharmacovigilance recommendations aim to standardize and improve haemophilia prophylaxis.
  • Further research is needed to optimize prophylactic regimens and long-term outcomes.
  • Future studies should employ rigorous methodologies, including defined cohorts and validated assessments.